Products with Anti-adipogenic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1030 | 6-Gingerol |
| 6-Gingerol possesses anti-adipogenic, anti-tumorigenic, anti-invasive, antioxidant, anti-inflammatory, and pro-apoptotic activities, it stimulates apoptosis through upregulation of NAG-1 and G1 cell cycle arrest through downregulation of cyclin D1, multiple mechanisms appear to be involved in 6-gingerol action, including protein degradation as well as β-catenin, PKCε, and GSK-3β pathways. 6-Gingerol can effectively suppress adipogenesis and that it exerts its role mainly through the significant down-regulation of PPARγ and C/EBPα and subsequently inhibits FAS and aP2 expression, also inhibit differentiation in 3T3-L1 cells by attenuating the Akt/GSK3β pathway. | |
| BCN1069 | Ginsenoside Rh1 |
| Ginsenoside Rh1 has anti-obesity, anti-inflammatory, antiallergic, and anti-tumor activities, it may improve glucocorticoid efficacy in hormone-dependent diseases. It inhibits MAPK and PI3K/Akt signaling pathways and downstream transcription factors such as NF-κB and AP-1, which play an important role in MMP gene expressions; it also inhibits IFN-gamma-induced JAK/STAT and ERK signaling pathways and downstream transcription factors, and thereby iNOS gene expression. | |
| BCN1072 | Ginsenoside Rc |
| Ginsenoside Rc exhibits anti-diabetic, anti-adipogenic, anticancer and anti-inflammatory activities; it can attenuate inflammatory symptoms of gastritis, hepatitis and arthritis, and it can significantly enhance glucose uptake by inducing ROS generation, which leads to AMPK and p38 MAPK activation. Rc enhances GABA receptorA (GABAA)-mediated ion channel currents (IGABA), it also inhibits the expression of TNF-α and IL-1β. | |
| BCN1245 | Ginsenoside F2 |
| Ginsenoside F2, an autophagic initiater, which has anti-cancer, and anti-obesity activities. Ginsenoside F2 inhibited the growth and invasion of cancer, and activated the intrinsic apoptotic pathway and mitochondrial dysfunction. Ginsenoside F2 suppresses hair cell apoptosis and premature entry to catagen more effectively than finasteride, it decreases the expression of TGF-β2 and SCAP proteins, the factors in the SCAP pathway could be targets for hair loss prevention drugs. | |
